Simantov Ronit 4

What Happened

• Director Ronit Simantov was granted a derivative award equivalent to 1,230 shares of Tempest Therapeutics (TPST) on January 27, 2026. The reported acquisition price was $0.00, so no cash changed hands at grant. This is an award/option-type grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-01-27; Filing date: 2026-01-28 (filed promptly).
• Reported terms: 1,230 shares; acquisition price $0.00 (derivative award).
• Vesting: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027 or (ii) the day of the issuer's 2026 annual stockholder meeting, subject to continuous service through the vesting date (per footnote).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Timeliness: Filing appears timely (reported the next day); no late-filing flag indicated.

Context

• This filing reports a grant of a derivative award (option/award) rather than an exercise or open-market trade. The award will only convert to actual vested shares if the vesting conditions are met, and there is no immediate sale or cashless exercise reported. Grants like this are common as compensation for directors and do not, by themselves, indicate a purchase or sale market signal.